Porton Pharma Solutions Ltd
SZSE:300363
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.22
25.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Porton Pharma Solutions Ltd
Total Current Liabilities
Porton Pharma Solutions Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Porton Pharma Solutions Ltd
SZSE:300363
|
Total Current Liabilities
¥1.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Current Liabilities
¥6.9B
|
CAGR 3-Years
37%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Total Current Liabilities
¥2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
26%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Current Liabilities
¥4.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Current Liabilities
¥13.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Current Liabilities
¥1.1B
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Porton Pharma Solutions Ltd
Glance View
Porton Pharma Solutions Ltd., rooted in the vibrant landscape of China's pharmaceutical sector, has strategically navigated its way to becoming a pivotal player in the global Contract Development and Manufacturing Organization (CDMO) industry. Founded in 2005, the company harnesses the intricate synergy between chemistry and biology to drive its core operations. Porton specializes in providing a comprehensive suite of services ranging from early drug development to commercial-scale manufacturing. The company's business model thrives on forming collaborative partnerships with global pharmaceutical and biotechnology firms, offering customized solutions tailored to specific drug production needs. By acting as an extension of its clients' research and development teams, Porton effectively reduces the time and investment required for its clients to bring new drugs to market, catalyzing its own revenue through long-standing service agreements. The essence of Porton’s value proposition lies in its robust technological capabilities and commitment to compliance with international quality standards, which ensures client trust and repeat business. Porton's facilities are outfitted with cutting-edge technologies that support complex chemical synthesis and advanced bioprocessing, allowing them to expertly handle high-potency and complex molecules. Additionally, the company leverages its strategic geographic advantage in China to offer competitive pricing while maintaining quality excellence, a crucial factor in contracting agreements. Through continuous investments in research and development, and a commitment to operational efficiency, Porton Pharma Solutions Ltd. not only accelerates its clients' drug development timelines but also enhances its own profitability, positioning itself as a leader in the evolving CDMO landscape.
See Also
What is Porton Pharma Solutions Ltd's Total Current Liabilities?
Total Current Liabilities
1.4B
CNY
Based on the financial report for Sep 30, 2024, Porton Pharma Solutions Ltd's Total Current Liabilities amounts to 1.4B CNY.
What is Porton Pharma Solutions Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
8%
Over the last year, the Total Current Liabilities growth was -7%. The average annual Total Current Liabilities growth rates for Porton Pharma Solutions Ltd have been -5% over the past three years , 10% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet
